Abstract
When conducting genome-wide association studies, improper handling of medication status that is relevant to the trait of interest can induce biases by opening up different pathways that distort estimates of the true effect. Here, we propose the genetic empirical medication reduction adjustment (GEMRA) method which uses a heuristic search for an empirical adjustment to be applied to phenotypic values of participants reporting medication use. Through simulations we show that the direct genetic effect estimates in the GEMRA approach exhibited less bias and greater statistical power than either restricting the sample to unmedicated users, or including all samples without adjustment. We then applied the GEMRA approach to estimate statin medication adjustment for analysis of LDL cholesterol levels, using multi ancestry data from UK Biobank and the Uganda Genome Resource. We found that a relative rather than an absolute adjustment better modelled the effect of medication on LDL cholesterol, with an effect of 40% reduction appearing to be consistent across ancestral groups. These findings are consistent with the current clinical guidelines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under Application No 15825. This project was supported by the UK Medical Research Council (MRC) as part of a network grant awarded to the MRC Integrative Epidemiology Unit at the University of Bristol (MC_UU_00011/4, MC_UU_00011/1, MC_UU_00032/01, MC_UU_00032/03), core funding to the MRC/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit under the MRC/UK Department of International Development (DFID) Concordat agreement with Segun Fatumo supported by the Wellcome Trust (220740/Z/20/Z), and the MRC Population Health Research Unit at the University of Oxford (MC_UU_00017/2). This study was also supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. This publication is the work of the authors who will serve as guarantors for the contents of this paper. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project used cohort data that received ethical approval. UK Biobank received ethical approval from the Research Ethics Committee (REC reference for UK Biobank is 11/NW/0382). The Ugandan Genome Resource was approved by the Science and Ethics Committee of the UVRI Research and Ethics Committee (UVRI-REC #HS 1978), the Uganda National Council for Science and Technology (UNCST #SS 4283), and the East of England-Cambridge South (formerly Cambridgeshire 4) NHS Research Ethics Committee UK.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All scripts used to perform these analyses are available at https://github.com/MRCIEU/bp-drug-mr/tree/main/analysis/gwas/ldlc_adj_med_analysis.
